3ZiniG,BainB,BettelheimP,et al.A European consensus report on blood cell identification:terminology utilized and morphological diagnosis concordance among 28 experts from 17 countries within the European LeukemiaNet network WP10,on behalf of the ELN Morphology Faculty [J].Br J Haematol,2010,151(4):359-364.doi:10.1111/j.1365-2141.2010.08366.x.
6Blade J,Lust JA,Kyle RA.Immunoglobulin D multiple myeloma:Presenting features,response to therpy,and survival in a series of 53 cases.J Clin Oncol,1994,12:2398-2404.
7Bataille R,Durie BG,Grenier J,et al.Prognostic factors and staging in multiple myeloma:a reappraisal.J Clin Oncol,1986,4:80-87.
8Shimamoto Y,Anami Y,Yamaguchi M.A new risk grouping for IgD myeloma based on analysis of 165 Japanese patients.Eur J Haematol,1991,47:262-267.
9Blade J, Lust JA, Kyle RA. Immunoglobulin D multiple myeloma: Presenting features, response to therapy, and survival in a series of 53 cases. J Clin Oncol, 1994, 12: 2398-2404.
10Dong C, Hemminki K. Second preimary neoplasms among 53, 159 haematolymphoproliferative malignancv patients in Sweden, 1958-1996: a search for common mechanisms. Br J Cancer, 2001, 85:997-1005.
